NCT06912035CompletedPhase 2/3
Efficacy of Diacerein Supplementation on Interleukin-1β, Hs-CRP, TNF-α Levels and Glycemic Control in Uncontrolled Type 2 Diabetes Mellitus Patients at Dr. Mohammad Hoesin General Hospital Palembang
EFFICACY OF DIACEREIN ADDITION ON INTERLEUKIN-1Β, HS-CRP, TNF-Α LEVELS AND GLYCEMIC CONTROL IN UNCONTROLLED TYPE 2 DIABETES MELLITUS PATIENTS AT DR. MOHAMMAD HOESIN GENERAL HOSPITAL PALEMBANG
Source: ClinicalTrials.gov · Last updated 4 Apr 2025
Brief summary (registry, in English)
The goal of this clinical trial is to learn if diacerein supplementation can help improve inflammation and glycemic control in adults with uncontrolled type 2 diabetes. It will also study the safety and tolerability of diacerein. The main questions it aims to answer are: * Does diacerein lower levels of inflammatory markers like interleukin-1β, hs-CRP, and TNF-α? * Does diacerein improve blood sugar control? * What side effects or problems do participants have when taking diacerein? Researchers will compare diacerein to a placebo (a look-alike substance with no active drug) to see if it works better for managing type 2 diabetes. Participants will: * Be adults aged 40-60 with uncontrolled type 2 diabetes * Take either diacerein or a placebo every day for 12 weeks * Visit the clinic for blood tests and monitoring at the beginning and end of the trial * Be evaluated for side effects and medication adherence\]
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 34 (actual)
- First submitted
- 28 Mar 2025
- Start date
- 21 Jun 2024
- Primary completion date
- 8 Nov 2024
- Lead sponsor
- Universitas Sriwijaya
- Diseases
- Type 2 diabetes
- NCT number
- NCT06912035
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 34
- From 21 Jun 2024 to the primary completion date, 8 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently receiving hormone replacement therapy.
- Use of other anti-inflammatory drugs within the past 2 weeks.
- Drop-out Criteria
- Patients who discontinue medication for more than 2 weeks.
- Occurrence of serious adverse drug reactions requiring discontinuation of the medication.
Other illness
- History of allergy to medications containing rhein.
- Severe liver disorders.
- Chronic kidney disease.
- Malignancy.
- Autoimmune diseases.
- Severe bacterial infection.
Other
- Pregnant or breastfeeding.
- Osteoarthritis.
- Death.
- Loss to follow-up.
Who the study is looking for
- Patients diagnosed with uncontrolled type 2 diabetes mellitus who are receiving treatment at Dr. Mohammad Hoesin General Hospital, Palembang.
- Male and female patients aged 40-59 years.
- Willing to participate in the study by signing the informed consent form.
Age in the registry: 60 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitas Sriwijaya Coordinator of this site? Confirm its status | Palembang | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.